Association of Promoter Hypermethylation of the RASSF1A Gene With Prognostic Parameters in Endometrial Cancer

$79.00 plus tax (Refund Policy)

Buy Article:

Abstract:

RASSF1A is a tumor suppressor gene that is frequently hypermethylated in various human cancers. In the present study, we examined RASSF1A methylation status in 70 patients with endometrial cancer to search for correlations between the promoter hypermethylation of RASSF1A and the clinicopathologic parameters. Thirty-six of 70 endometrial cancers demonstrated hypermethylation of the RASSF1A promoter. Advanced stage disease (FIGO stage III, IV), lymph node involvement, and high grade (G3) are more frequent in patients with RASSF1A hypermethylation than in those without. We also observed a higher incidence of recurrences and lower disease-free survival (DFS) in patients with RASSF1A hypermethylation (77.8% and 97.0% at 5 years for methylated and unmethylated patients, respectively, p = 0.039). Our results suggest that RASSF1A hypermethylation might be a useful indicator of tumor aggressiveness in endometrial cancer patients.

Keywords: Endometrial cancer; Hypermethylation; Pathologic parameters; Prognosis; RASSF1A

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/000000006783981125

Affiliations: 1: Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea 2: Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea, Cancer Research Institute, Seoul National University, Seoul, Korea, Human Genome Research Institute, Seoul National University, Seoul, Korea 3: Cancer Research Institute, Seoul National University, Seoul, Korea, Human Genome Research Institute, Seoul National University, Seoul, Korea 4: Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea, Cancer Research Institute, Seoul National University, Seoul, Korea

Publication date: April 1, 2006

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more